After waffling, Qiagen agrees to $11.5B buyout by Thermo Fisher

Thermo Fisher Scientific plans to acquire Qiagen in a deal valued at $11.5B, putting an end to doubts first voiced last November. The deal is expected to be finalized in the first half of 2021.

By acquiring Qiagen’s products, Thermo Fisher hopes to gain a stronger foothold in molecular diagnostics and infectious disease and is aiming for cost savings totaling $200M by the third year after closing.